Biosimilars and Biobetters September 25, 2011

SMi is proud to present its 2nd conference on Biosimilars and Biobetters that will bring together leading figures in the growing market. With billions of dollars worth of biologic drugs going off patient in the next decade, this industry in set to expand at an intensive rate, and the importance of being fully informed of how you and our business will be affected is paramount. By the same token, the rewards of playing an important role in the development of biosimilars, or “Follow On Biologics”, are potentially substantial.

This year’s key presentations include:

Next generation monoclonal antibody development and clinical challenges with
biosimilar drug development - Frank Scappaticci, Associate Group Medical Director, Genentech

The developing biosimilars regulatory framework in the U.S. - Ross Lobell, Vice President, Regulatory Affairs, Medimmune

Factors to be considered for Biosimilar CMC development - Hans-Martin Mueller, Associate Director, Biotech Development, Merck

GCSF biosimilar case study - Matthew Turner, Global Medical Leader - Zarzio and Binocrit, Sandoz Biopharmaceuticals

Biosimilar sales forecast in seven unregulated markets in 2016: How large is the opportunity? - Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
PLUS! Two interactive post-conference workshops:
How Similar is Similar?
Hosted by: Peter Wittner, Senior Consultant, Interpharm Consultancy
Wednesday 28th September 2011
8.30pm – 12.30pm, Copthorne Tara Hotel

A Global View of Biosimilars: Regulatory Analysis and Pricing Structure Case Studies
Hosted By: Milena Izmirlieva, Senior Analyst, IHS Global Insight
Floriane Reinaud, Senior Analyst, IHS Global Insight
Wednesday 28th September 2011
1.30pm – 5.30pm, Copthorne Tara Hotel

Official Website: http://www.smi-online.co.uk/2011biosimilars38.asp